Greywolf Therapeutics
UK - OxfordBiotechnology
Focus: Greywolf Therapeutics is a UK-based biotechnology company specializing in modulating ERAP1 and ERAP2 proteins for immuno-oncology applications. The company is in Series B stage, positioning itself as a focused player in the oncology immunotherapy space.
Profile data last refreshed 18h ago · AI intelligence enriched 2w ago
Funding Stage
SERIES B
Total Funding
$131M
Open Jobs
1-2 this month
Stable — net -2 jobs in 30d
1 added, 3 removed. Backfill posture.
Should You Work at Greywolf Therapeutics?
AI assessmentGreywolf is a potentially high-potential immuno-oncology specialist, but severe data opacity makes career risk assessment unreliable; due diligence on science and finances essential before committing.
Why Work Here
- Focused therapeutic approach targeting ERAP1/ERAP2 represents a differentiated immuno-oncology strategy with potential for breakthrough designation
Data completeness
1/9 — Limited
Company HealthSolid
Pipeline
Early-stage
0 total
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Interview Prep Quick Facts
Help build intelligence for Greywolf Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.